


ML-SA5

Cat. No.:	HY-152182
CAS No.:	2418670-70-7
Molecular Formula:	C ₁₉ H ₂₄ ClN ₃ O ₄ S ₂
Molecular Weight:	457.99
Target:	TRP Channel
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (272.93 mM; Need ultrasonic)																					
	<table border="1"> <thead> <tr> <th rowspan="2">Solvent</th> <th rowspan="2">Mass</th> <th colspan="3">Concentration</th> </tr> <tr> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Preparing Stock Solutions</td> <td>1 mM</td> <td>2.1835 mL</td> <td>10.9173 mL</td> <td>21.8345 mL</td> </tr> <tr> <td>5 mM</td> <td>0.4367 mL</td> <td>2.1835 mL</td> <td>4.3669 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2183 mL</td> <td>1.0917 mL</td> <td>2.1835 mL</td> </tr> </tbody> </table>	Solvent	Mass	Concentration			1 mg	5 mg	10 mg	Preparing Stock Solutions	1 mM	2.1835 mL	10.9173 mL	21.8345 mL	5 mM	0.4367 mL	2.1835 mL	4.3669 mL	10 mM	0.2183 mL	1.0917 mL	2.1835 mL
Solvent	Mass			Concentration																		
		1 mg	5 mg	10 mg																		
Preparing Stock Solutions	1 mM	2.1835 mL	10.9173 mL	21.8345 mL																		
	5 mM	0.4367 mL	2.1835 mL	4.3669 mL																		
	10 mM	0.2183 mL	1.0917 mL	2.1835 mL																		
	Please refer to the solubility information to select the appropriate solvent.																					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.54 mM); Clear solution 																					

BIOLOGICAL ACTIVITY

Description	ML-SA5 is a potent TRPML1 cation channel agonist that activates the entire endosomal TRPML1 (ML1) current in DMD myocytes with an EC ₅₀ of 285 nM and is more potent than ML-SA1. ML-SA5 has anticancer activity and can inhibit tumour growth ^[1] .
In Vitro	ML-SA5(1-100 μM, 24 h) has some cell-targeting specificity and induces substantial cell death in M12 and MeWo cells, but fully preserves normal melanocytes. It also causes a loss of mitochondrial membrane potential in M12 cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ML-SA5 (i.p., 2-5 mg/kg, daily, 2 weeks) reduces muscle necrosis in MDX mice by more than 70% and reduces central nucleated fibers, suggesting that ML-SA5 can improve muscle atrophy in mdx mice in vivo by promoting myosin repair, but has no effect in ML1 knockout mice. Moreover, ML-SA5 reduces skeletal and cardiac muscle damage in mdx mice through

ML1 upregulation^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wanlu Du, et al. Lysosomal Zn²⁺ release triggers rapid, mitochondria-mediated, non-apoptotic cell death in metastatic melanoma. *Cell Rep.* 2021 Oct 19;37(3):109848.

[2]. Lu Yu, et al. Small-molecule activation of lysosomal TRP channels ameliorates Duchenne muscular dystrophy in mouse models. *Sci Adv.* 2020 Feb 7;6(6):eaaz2736.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA